These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 4997816)

  • 41. Co-operative controlled trial of a standard regimen of streptomycin, PAS and isoniazid and three alternative regimens of chemotherapy in Britain. A report from the British Medical Research Council.
    Tubercle; 1973 Jun; 54(2):99-129. PubMed ID: 4203162
    [No Abstract]   [Full Text] [Related]  

  • 42. [Assessment of the use of a multicomponent drug in the treatment of new cases of pulmonary tuberculosis].
    Semenova OV
    Probl Tuberk Bolezn Legk; 2003; (11):22-5. PubMed ID: 14689793
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Rifampicin and ethanbutol in daily and intermittent treatment of chronic advanced cavernous pulmonary tuberculosis resistant to many drugs. Preliminary communication. Early results].
    Zierski M; Bek E; Kucharska A; Graczyk J; Bukalska Z
    Gruzlica; 1973 Nov; 41(11):1129-37. PubMed ID: 4765793
    [No Abstract]   [Full Text] [Related]  

  • 44. Drug resistance to the first line of antitubercular regimen (a preliminary report).
    Varaiya A; Gogate A
    Indian J Public Health; 1998; 42(4):126-30. PubMed ID: 10389525
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapeutic efficacy of rifampin in newly detected pulmonary tuberculosis.
    Jessamine AG; Gale GL; Eidus L
    Can Med Assoc J; 1974 May; 110(9):1033-7. PubMed ID: 4207234
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Controlled therapeutic trial with the combination rifampicin-isoniazid given for six months to previously untreated patients with pulmonary tuberculosis.
    Dubra F
    Bull Int Union Tuberc; 1972 Feb; 47():37-40. PubMed ID: 4562016
    [No Abstract]   [Full Text] [Related]  

  • 47. Drug susceptibility in Mycobacterium tuberculosis of a sample of patients in Guinea Bissau.
    Dias F; Michael SG; Hoffner SE; Martins L; Norberg R; Källenius G
    Tuber Lung Dis; 1993 Apr; 74(2):129-30. PubMed ID: 8324205
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
    Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):707-12. PubMed ID: 1901200
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Results of 6-month and 9-month treatments with rifampin, isoniazid and ethambutol in cases of newly detected tuberculosis].
    Szymanski A; Gaik A
    Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol; 1981; 30(3):181-3. PubMed ID: 6273991
    [No Abstract]   [Full Text] [Related]  

  • 50. [Intermittent chemotherapy of pulmonary tuberculosis with rifampicin and ethambutol].
    Virsik K; Kruty R; Matula F; Badalik L
    Probl Tuberk; 1978 Oct; (10):28-30. PubMed ID: 714902
    [No Abstract]   [Full Text] [Related]  

  • 51. Trends in the prevalence of primary drug resistance in pulmonary tuberculosis in France from 1962 to 1970: a national survey.
    Canetti G; Gay P; Le Lirzin M
    Tubercle; 1972 Jun; 53(2):57-83. PubMed ID: 4114335
    [No Abstract]   [Full Text] [Related]  

  • 52. Rifampin-isoniazid compared with PAS-isoniazid-streptomycin in initial treatment of pulmonary tuberculosis. A controlled cooperative trial.
    Boman G
    Chest; 1972 Jun; 61(6):533-8. PubMed ID: 5032151
    [No Abstract]   [Full Text] [Related]  

  • 53. Rifampicin plus isoniazid, rifampicin plus PAS, and isoniazid plus PAS in the initial treatment of pulmonary tuberculosis. A controlled multicenter clinical trial.
    Tousek J; Votruba R
    Chemotherapy; 1974; 20(3):183-200. PubMed ID: 4605071
    [No Abstract]   [Full Text] [Related]  

  • 54. The Australian rifampicin trial.
    Proust A; Evans C
    Med J Aust; 1972 Oct; 2(16):861-7. PubMed ID: 4647286
    [No Abstract]   [Full Text] [Related]  

  • 55. Experimental and clinical studies on the antituberculous activity of rifampicin alone or combined with other drugs.
    Nitti V
    Antibiot Chemother; 1970; 16():444-70. PubMed ID: 5002308
    [No Abstract]   [Full Text] [Related]  

  • 56. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Hong Kong Chest Service/British Medical Research Council.
    Tuber Lung Dis; 1992 Feb; 73(1):59-67. PubMed ID: 1326349
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical effect of rifampicin-ethambutol isoniazid on untreated pulmonary tuberculosis.
    Konno K; Oizumi K; Yamada S; Ogata K; Sato M
    Sci Rep Res Inst Tohoku Univ Med; 1972 Sep; 19(2):68-72. PubMed ID: 4649624
    [No Abstract]   [Full Text] [Related]  

  • 58. Primary drug-resistant tuberculosis in active-duty military personnel: 1959-1968.
    Briney RR; Cowley RG
    Am Rev Respir Dis; 1970 May; 101(5):700-2. PubMed ID: 4986424
    [No Abstract]   [Full Text] [Related]  

  • 59. A comparative study of daily followed by twice- or once-weekly regimens of ethambutol and rifampicin in the retreatment of patients with pulmonary tuberculosis: second report.
    Tubercle; 1976 Jun; 57(2):105-13. PubMed ID: 822547
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Analytical study of the treatment of 18 cases of chronic open pulmonary tuberculosis with secondary resistance to rifampicin.
    Lukas W
    Respiration; 1971; 28():Suppl:70-83. PubMed ID: 5150796
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.